stella
beta
An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID) — Stella
Recruiting
Back to Primary Immunodeficiency trials
Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations
(8 sites)
United States
Research Solutions of AZ, Litchfield Park, Arizona
Medical Research of Arizona, Scottsdale, Arizona
Immunoe Health Centers, Centennial, Colorado
Johns Hopkins Bayview Medical Center, Baltimore, Maryland
Midwest Immunology, Plymouth, Minnesota
Show all 8 locations
View full record on ClinicalTrials.gov